期刊文献+

显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究 被引量:29

Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer
原文传递
导出
摘要 目的探讨显色原位杂交(CISH)在检测乳腺癌中 HER2/neu 基因扩增上的作用。方法挑选乳腺浸润性导管癌患者组织石蜡蜡块(回顾性255例,前瞻性271例),进行免疫组织化学(IHC)、CISH 检测。15例回顾性标本送往德国 HERA 检测中心进行 FISH 检测。结果 (1)回顾性病例中 IHC 阳性3+者 CISH 基因扩增率为91.6%(120/131),IHC 2+者 CISH 基因扩增率为56.5%(39/69),IHC 与 CISH 检测结果符合率为81.2%(207/255),两者明显相关(P<0.01)。(2)前瞻性病例中 IHC 蛋白过表达率31.7%,CISH 基因扩增率27.3%。IHC 3+者 CISH 基因扩增率为91.4%(53/58),IHC 2+者 CISH 基因扩增率为46.4%(13/28),IHC 与 CISH 检测结果符合率为89.7%(243/271),两者明显相关(P<0.01)。(3)经德国检测中心荧光原位杂交(FISH)检测的15例中14例和 CISH 结果完全一致,1例检测失败,而 CISH 为无扩增。(4)CISH 检测基因扩增与雌激素受体(ER)、孕激素受体(PR)表达明显负相关(P 值均<0.01)。结论 CISH 检测 HER2基因扩增结果与IHC 检测蛋白过表达及 FISH 结果高度一致,CISH 是检测 HER2基因扩增的一项新技术。 Objective Through comparision of HER2/neu oncogene detected by chromogenic in situ hybridization (CISH) and immunohistoehemistry (IHC) in breast cancer, to explore the effect of CISH on detecting gene amplification of HER2. Methods Selected formalin-fixed paraffin-embedded breast samples whose pathological types were infiltrating duetal carcinomas (255 retrospective samples, 271 prospective samples ) , and these samples were detected by IHC and CISH. Results (1) In the retrospective study, CISH identified gene amplification in 91.6% of IHC score 3 + tumors ( 120/131 ) and in 56. 5% of IHC score 2 + tumors(39/69), thus the concordant ratio between IHC and CISH was 81.2% (207/255). The two results showed significant correlation (P 〈 0. 01 ). (2) In the prospective study, the ratio of HER2 protein over expression detected by IHC was 31.7% , the ratio of HER2 gene amplification detected by CISH was 27. 3%. CISH identified gene amplification in 91.4% of IHC score 3 + tumors (53/58) and in 46.4% of IHC score 2 + tumors ( 13/28), Concordant ratio between IHC and CISH was 89. 7% (243/271). Two results showed significant correlation ( P 〈 0. 01 ). ( 3 ) Paired CISH/FISH results were concordant in 14 of 15 cases. The remaining case was detected by FISH, but showed no HER2 gene amplification by CISH. (4)The gene amplification by CISH had a significantly reverse correlation with ER and PR expression ( P 〈 0.01 ). Conclusions The results of HER2 gene amplification detected by CISH have high concordance with the results detectd by IHC and FISH. CISH is a novel technique for detecting HER2 gene amplification.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2006年第10期580-583,共4页 Chinese Journal of Pathology
关键词 乳腺肿瘤 基因 ERBB-2 免疫组织化学 原位杂交 Breast neoplasms Genes, erbB-2 Immunohistoehemistry In situ hybridization
  • 相关文献

参考文献12

  • 1Ross JS,Fletcher JA.HER-2/neu (c-erb-B2) gene and protein in breast cancer.Am J Clin Pathol,1999,112 (1 Suppl 1):553-567.
  • 2Gouvea AP,Milanezi F,Olson SJ,et al.Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.Appl Immunohistochem Mol Morphol,2006,14:103-108.
  • 3Shak S.Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999(4 Suppl 12),26:71-77.
  • 4Tanner M,Gancberg D,DiLeo A,et al.Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.Am J Pathol,2000,157:1467-1472.
  • 5Madrid MA,Lo RW.Chromogenic in situ hybridization (CISH):a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.Breast Cancer Res,2004,6:R593-R600.
  • 6Todorovic-Rakovic N,Jovanovic D,Neskovic-Konstantinovic Z,et al.Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.Pathol Int,2005,55:318-323.
  • 7Tubbs RR,Pettay JD,Roche PC,et al.Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy:apparent immunohistochemical false-positives do not get the message.J Clin Oncol,2001,19:2714-2721.
  • 8Jacobs TW,Gown AM,Yaziji H,et al.Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.J Clin Oncol,1999,17:1983-1987.
  • 9Jacobs TW,Gown AM,Yaziji H,et al.Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.J Clin Oncol,1999,17:1974-1982.
  • 10Zhao J,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Mod Pathol,2002,15:657-665.

同被引文献323

引证文献29

二级引证文献676

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部